United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee Recognizes New Therapeutic Class by Granting “nibrozetone” as New Generic Name for EpicentRx’s Lead Small Molecule NLRP3 Inhibitor, RRx-001

ByDonato

Jul 6, 2023 #“nibrozetone”, #epicentrx’s, #inhibitor,, #international, #nonproprietary, #recognizes, #states, #therapeutic, #united

-New USAN name, a shortening of its chemical name, signifies a novel therapeutic class

-Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs

TORREY PINES, Calif., July 6, 2023 /PRNewswire/ — EpicentRx, Inc., a clinical stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, today announced that the United States Adopted Name (USAN) Council in consultation with the World Health Organization’s (WHO) International Nonproprietary Names (INN) Expert Committee has assigned the generic name "nibrozetone", a shortening of the chemical name, alpha-bromodinitroazetidine, for its lead […]

Click here to visit source. www.prnewswire.com